
Camurus Q1 2025 - Buvidal On Target, Brixadi Flat

Redeye comments on Camurus' first quarter report 2025, which saw Buvidal sales on track, but Brixadi sales were flat Q/Q on a constant FX basis. We believe the slack in growth is temporary, but we reduce the projected near- and medium-term sales of Brixadi slightly.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Camurus Q1 2025 - Buvidal On Target, Brixadi Flat